Mesenchymal stromal cells for cutaneous wound healing in a rabbit model: pre-clinical study applicable in the pediatric surgical setting

Gloria Pelizzo, Maria Antonietta Avanzini, Antonio Icaro Cornaglia, Monica Osti, Piero Romano, Luigi Avolio, Rita Maccario, Massimo Dominici, Annalisa De Silvestri, Erika Andreatta, Federico Costanzo, Melissa Mantelli, Daniela Ingo, Serena Piccinno and Valeria Calcaterra

Abstract

Objective: Mesenchymal stromal cells (MSCs) expanded in vitro have been proposed as a potential therapy for congenital or acquired skin defects in pediatrics. The aim of this pre-clinical study was to investigate the effects of intradermal injections of MSC in experimental cutaneous wound repair comparing allogeneic and autologous adipose stem cells (ASCs) and autologous bone marrow-mesenchymal stromal cells (BM-MSCs).

Methods: Mesenchymal stromal cells were in vitro expanded from adipose and BM tissues of young female New Zealand rabbits. MSCs were characterized for plastic adhesion, surface markers, proliferation and differentiation capacity. When an adequate number of cells (ASCs $10^6$ and BM-MSCs $3 \times 10^6$, because of their low rate of proliferation) was reached, two skin wounds were surgically induced in each animal. The first was topically treated with cell infusions, the second was used as a control. The intradermal inoculation included autologous or allogeneic ASCs or autologous BM-MSCs. For histological examination, animals were sacrificed and wounds were harvested after 11 and 21 days of treatment.

Results: Rabbit ASCs were isolated and expanded in vitro with relative abundance, cells expressed typical surface markers (CD49e, CD90 and CD29). Topically, ASC inoculation provided more rapid wound healing than BM-MSCs and controls. Improved re-epithelization, reduced inflammatory infiltration and increased collagen deposition were observed in biopsies from wounds treated with ASCs, with the best result in the autologous setting. ASCs also improved restoration of skin architecture during wound healing.

Conclusion: The use of ASCs may offer a promising solution to treat extended wounds. Pre-clinical studies are however necessary to validate the best skin regeneration technique, which could be used in pediatric surgical translational research.

Keywords: Mesenchymal stromal cells, Cutaneous wounds, Adipose, Bone marrow, Pediatric surgery, Regenerative medicine
Background
Renewal and maintenance of normal skin depend on a pool of endogenous progenitors. After skin injury, a series of coordinated events occur, including bleeding and coagulation, acute inflammation, cell migration, proliferation, differentiation, angiogenesis, re-epithelialization, and synthesis as well as remodelling of the extracellular matrix. These complex events involve three overlapping phases: inflammation, proliferation and remodelling [1–4]. In the normal healing process, all of the above stages function sequentially and for a specific amount of time. However, interference during the wound healing process may prolong one or more of these phases leading to delayed or incomplete wound healing.

Recent advances in stem cell therapy for tissue engineering approaches have provided promising data on wound repair and tissue regeneration. Mesenchymal stromal cells (MSCs) expanded in vitro have been proposed as a potential therapy to enhance cutaneous wound healing [5–11]. It has been described that MSCs may attenuate the inflammatory response by influencing the wound’s ability to progress beyond the inflammatory phase and not regress to a chronic wound state [12, 13].

MSCs are multipotent cells that can differentiate into multiple tissue-forming cell lineages, such as osteoblasts, adipocytes, chondrocytes, tenocytes, and myocytes. In addition, MSCs regulate immune and inflammatory responses. These multipotent cells with innate self-renewal capacity can be in vitro expanded without losing their differentiation potential. MSCs have been isolated from various tissues such as bone marrow (BM), umbilical cord blood, skeletal muscle and brain. Additionally, they can be easily obtained in large quantities with minimal invasiveness from adipose tissue, the so-called adipose stem cells (ASCs) [14, 15]. Although BM-MSCs and ASCs share many biological features, there are some differences between these distinct MSC populations. For instance ASCs show a higher proliferative capacity and retain differentiation potential for a longer period in culture compared with human BM-MSCs. Moreover it has been demonstrated that human ASCs support hematopoiesis both in vitro and in vivo more efficiently than human BM-MSCs, on the other hand it has been suggested that BM-MSCs evoke less inflammation and thrombogenesis than ASC [16].

The therapeutic effects of MSCs have already been demonstrated in preclinical and clinical studies in adults [6]. Their strong capacity to proliferate and differentiate and their immunomodulatory effects support their potential use in safe regenerative medicine approaches also in pediatric patients [17]. In the presence of extensive and disfiguring congenital pathologies, impaired wound healing remains a challenge and causes debilitating effects with tremendous suffering. This is the case with giant congenital melanocytic nevi, where complete surgical removal is difficult to achieve because of the lack of available skin to graft over the resultant defects [18, 19] or following acquired skin lesions such as burn wounds or tissue destruction following surgery or trauma in which skin damage usually never fully recovers [20, 21].

In these cases, ASCs or BM-MSCs represent tools which could potentially provide mechanical and humoral support for skin regeneration for better functional and cosmetic results. However, the use of MSC therapy to improve wound healing is limited as a widely used and proven cell source is not rapidly available after injury. In fact, the time necessary to ex vivo expand sufficient autologous cell numbers is extensive. The alternative is to use allogeneic cells that can be pre-expanded and characterised, and thus ready for use in the initial stages of injury.

The aim of this pre-clinical study was to investigate the advantage of using autologous ASCs over BM-MSCs, evaluating the effects of intradermal injections in experimental cutaneous wounds. Our purpose was to obtain a model which could be translated to the pediatric surgical setting. Considering the technical difficulties in obtaining adipose tissue in the pediatric age compared to the adult age and knowledge that age negatively impacts the biologic features of MSCs [22], we used young animals. Allogenic ASCs were also considered as an alternative source when autologous ASC isolation would be difficult, such as in neonates or young infants.

Methods
Adipose tissue and bone marrow harvest
Healthy young female New Zealand rabbits (n = 27, 3 months old, median 3.5 kg weight) [23], were used as an animal model. The experimental protocol was approved by the National Animal Care and Ethics Committee and conducted in accordance with Italian and European legislation (D.lgs. 116/92, European Directives 86/609/EE and 2010-63UE for the protection of animals used in scientific and experimental studies).

After overnight fasting, experimental animals were premedicated with an intramuscular midazolam injection (1 mg/kg). Under general anesthesia using Zoletil 0.4 ml/kg (Virbac, Milano, Italy), and after local anesthesia with levo-bupivacaine 0.25% or ropivacaine 0.2% (2 ml/cm wound), a 2 cm longitudinal incision was performed in the inguinal area in order to harvest adipose panicle (lipectomy), while BM was harvested by aspiration from the femoral medullary cavities.

Local anesthesia with levo-bupivacaine 0.25% or ropivacaine 0.2% (2 ml/cm wound) were repeated for pain...
management. Subcutaneous Enrofloxacin (0.1 ml/2 kg/day for 3 days—Bayer, Milano, Italy) and Meloxicam (0.3 mg/kg/day for 3 days—Boehringer Ingelheim, Milano, Italy) were subsequently administered.

**Isolation and culture of ASCs and BM-MSCs**

Inguinal fat pads were placed in sterile phosphate-buffered saline (PBS, Euroclone, Milan, Italy) with gentamicin, minced manually and digested with 0.0075% type II collagenase (3 mg/ml, Sigma-Aldrich, St Louis, MO, USA) in Dulbecco’s modified Eagle Medium (DMEM, Gibco, Invitrogen, Monza, Italy) for 20 min at 37°C with gentle agitation. The stromal vascular fraction (SVF), containing ASCs, was suspended in DMEM +10% Fetal Bovine Serum (FBS, Euroclone), in order to inhibit enzyme activity. The specimen was then filtered through a 100 mm sterile nylon mesh filter (Millipore, Darmstadt, Germany), and centrifuged at 1,200 rpm for 10 min. The resultant pellet was suspended and counted with 0.4% Trypan blue (Sigma-Aldrich). Cells were subsequently plated in culture flasks (Corning Costar, Amsterdam, The Netherlands) at a density of 160,000/cm² in αMEM (Gibco, Invitrogen) containing 10% FBS (Euroclone) and 1% antibiotic–antimycotic (Sigma-Aldrich) at 37°C, 5% CO₂ in a humidified atmosphere.

Mononuclear cells (MNC) were isolated from 1 ml of BM aspirate, by density gradient centrifugation (Ficoll 1.077 g/ml; Lympholyte, Cedarlane Laboratories Ltd., The Netherlands) counted and plated in 75 or 175 cm² tissue culture flasks at a density of 160,000/cm² in αMEM supplemented with 10% FBS (Euroclone) and 1% antibiotic–antimycotic (Sigma-Aldrich). Cultures were maintained at 37°C, 5% CO₂ in a humidified atmosphere. After 48-h, non-adherent cells were removed and culture medium was replaced twice a week. At each passage, viable cells were counted using 0.1% eosin and culture supernatants were tested for sterility.

**Immunophenotype**

Rabbit ASCs and BM-MSCs were characterized by flow cytometry. Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal antibodies (BD PharMingen, San Diego, CA, USA) anti-human CD29, anti-rat CD45, anti-human CD49e, anti-human CD10 and anti-rat CD90 cross-reactive against rabbit were used as described [24]. Appropriate, isotype-matched, irrelevant fluorochrome-conjugated antibodies were used as controls.

**Differentiation assays**

ASCs and BM-MSCs were evaluated for their ability to differentiate into osteoblasts and adipocytes, as previously described [25].

The osteogenic differentiation capacity of ASCs and BM-MSCs was assessed at P2–4 by incubating cells with αMEM, 10% FBS, 1% gentamicin, supplemented with 10⁻⁷ M dexamethasone (Sigma-Aldrich St Louis, MO, USA), 50 mg/ml l-ascorbic acid (Sigma-Aldrich). Starting from day +7 of culture, 5 mM β-glycerol phosphate (Sigma-Aldrich) was added to the medium. Adipogenic differentiation was evaluated at P2–4 by incubating cells with αMEM, 10% FBS, 1% gentamicin supplemented with 10⁻⁷M dexamethasone, 50 mg/ml l-ascorbic acid, 100 mg/ml insulin, 50 mM isobutyl-methylxanthine (Sigma-Aldrich), 0.5 mM indomethacin (MP Biomedica, Illkirch, France) and 5 mM β-glycerol phosphate. Both osteogenic and adipogenic cultures were incubated for 21 days before evaluating differentiation. To detect osteogenic differentiation, cells were stained for alkaline phosphatase (AP) activity using Fast Blue (Sigma-Aldrich) and, for calcium deposition, by Alizarin Red S staining (Sigma-Aldrich). Adipogenic differentiation was evaluated through the morphological appearance of fat droplets stained with Oil Red O (Bio Optica, Milan, Italy).

**Semi-solid clonogenic assay**

A suspension of 200,000 cells in D-MEM low glucose (Gibco), 0.9% methylcellulose (StemCell Technologies, Milan, Italy), 30% (vol/vol) FBS (StemCell Technologies) was plated in six-well plates. After 4 weeks incubation at 37°C in a humidified atmosphere with 5% CO₂, the plates were examined with contrast phase microscopy (4×) for the formation of colonies with an inverted microscope (Leitz, Wetzlar, Germany). A malignant transformed rat MSC line, obtained in our laboratory, was used as a positive control.

**Senescence assay**

Rabbit ASCs and BM-MSCs were maintained in culture until reaching senescence. They were closely monitored during senescence for up to 8–12 weeks before interrupting the cultures, in order to reveal any change in morphology and/or proliferation rate. MSC senescence was assessed by staining with the β-galactosidase (SA-β-gal) staining kit (Cell Signaling Technology, Danvers, MA, USA), according to the manufacturer’s instructions, and evaluated by direct-light microscopy.
Rabbit cutaneous wound model
When an adequate number of cells was reached, the skin wounds were surgically induced. After overnight fasting, experimental animals was premedicated with intramuscular midazolam (1 mg/kg). Under general anesthesia using Zoletil 0.4 ml/kg, and after local anesthesia with levo-bupivacaine 0.25% or ropivacaine 0.2% (2 ml/cm wound), two identical full thickness 2 × 2 cm wounds were created on the back of each rabbit, at a distance of more than 2 cm from each other. One lesion was used as a control. After creation of the wounds, local anesthesia with levo-bupivacaine 0.25% or ropivacaine 0.2% (2 ml/cm wound) was repeated. Subcutaneous Enrofloxacin (0.1 ml/2 kg/day for 3 days) and Meloxicam (0.3 mg/kg/day for 3 days) were subsequently administered.

Intradermal injection of ASCs and BM-MSCs
Within 5 min from the wound lesion establishment, autologous or allogeneic ASCs or autologous BM-MSCs in 3 ml of saline, 2% rabbit albumin (Sigma-Aldrich) were directly injected into the wound bed of the first lesion. The protocol called for infusions of 10 × 10^6 cells into the wound bed. An injection of 3 ml of saline, 2% rabbit albumin solution was used as a control in the second lesion. Rabbits did not receive any immune suppression. General conditions of the animals and wound healing were monitored daily. Wounds were photographed using a digital camera.

For the experimental outline see Figure 1.

Histological and immunohistochemical analyses
Rabbits were euthanized with a bolus of Pentobarbital 100 mg/kg IV. For histological examination, wounds were harvested after 11 (12 rabbits) and 21 days (15 rabbits) of treatment. The regenerated tissue biopsies were collected using dermal biopsy punches. The samples were bisected along the length of the wound, fixed in 4% neutral buffered formalin for 48 h, dehydrated with a gradient alcohol series, cleared in xylene and eventually embedded in paraffin. Sections (8 μm) were obtained using a Leitz microtome and prepared for histology. All stained slides were examined under an Axiohot Zeiss light microscope (Oberkochen, Germany) equipped with a digital camera.

To compare the re-epithelization rate and the amount of inflammatory infiltration, tissue sections were stained with haematoxylin and eosin (H&E). To assess the degree of collagen synthesis, Mallory’s trichrome stain was used, while immunohistochemical evaluation of proliferation was performed by anti-Proliferating Cell Nuclear Antigen (PCNA) antibody (Dako, Glostrup, Denmark). In this latter case, tissue sections were deparaffinized, hydrated and pretreated for antigen retrieval using a pressure cooker in 10 mM citrate buffer. Endogenous peroxidases were quenched with 3% hydrogen peroxide for 15 min. Non-specific antibody binding was blocked by incubation with a protein blocker (Dako). The sections were incubated with 1:400 anti-PCNA antibody or bovine serum albumin as a negative control for 30 min at 45°C, then incubated with horseradish peroxidase conjugated anti-mouse immunoglobulin (Dako) for 15 min at 45°C, followed by a 5 min incubation with
3,3′-diaminobenzidine (DAB; Dako). Finally, the sections were mounted and examined under a light microscope [26].

The re-epithelization rate defined as the presence of differentiated multi-layered epithelium, the amount of inflammatory infiltration defined as the presence of inflammatory cells [27], the degree of collagen defined as collagen content in granulation tissue and cellular proliferation, defined as PCNA positive nuclei/mm of epidermis or /mm² of dermis were assessed using a semi-quantitative scale, with scores ranging from 0 to 3 as reported in Table 1. The 39 biopsies were examined by two independent operators.

**Statistical analysis**
Quantitative data and the histological score were described as the median and interquartile range (IQR: 25th–75th centile) and compared by fitting multivariable ordinal logistic regression models with robust standard errors to take into account the clustered structure of the data. Groups (using controls as a reference) and times (using 11 days as a reference) were included in the models as independent variables.

Statistical significance was defined as a p value <0.05. Since no time effect was observed we reported only the p values (obtained in the multivariable ordinal logistic regression models i.e. corrected for time) relative to group comparisons. Data analysis was performed with the STATA statistical package (release 13.1.2012, Stata Corporation, College Station, TX, USA).

**Results**

**ASC and BM-MSC expansion rate and intradermal inoculation**
ASCs were isolated from all rabbits and expanded to P4, while BM-MSCs were isolated and expanded to P3 in 4 out of 27 rabbits. The expansion rate, defined as the calculated cell count (ccc), for BM-MSC was significantly lower (p = 0.028) than ASCs, with a mean ccc value of $6.59 \times 10^6 \pm 4.85 \times 10^6$ at P3 and $199 \times 10^6 \pm 263 \times 10^6$ at P4, respectively. Moreover the time to reach confluence was longer for BM-MSC than ASC (median 13 days, range 8–21 day; median 6.5 days, range 3–11 day, respectively).

Due to this low rate of in vitro expansion and restrictions on the length of time to ethically and legally house the rabbits, we were only able to expand a lower number of BM-MSC. Even though, the original protocol called for infusions of $10 \times 10^6$ cells into the wound bed, we decided to proceed with $3 \times 10^6$ of BM-MSCs only in the autologous setting.

In order to compare results between ASC and BM-MSCs infusion, four rabbits were treated with a comparable number of ASCs.

**ASC and BM-MSC characterization**
ASCs and BM-MSCs showed the typical spindle shape morphology (Figure 2, Panel A) and they resulted positive for CD49e, CD90 and CD29, while they were negative for CD45 and CD10 (Figure 2, Panel B for in vitro-expanded ASCs) as reported by Piccinno et al. [21].

Both ASCs and BM-MSCs exhibited the capacity to differentiate in vitro to osteoblasts and adipocytes as confirmed by histological staining. Microscopic examination of stained cells demonstrated the presence of mineralization nodules and fat droplets (Figure 2, Panel C). Both types of mesenchymal progenitors ceased their growth at variable passages and entered into the senescence phase (data not shown), moreover the three lots tested were not capable of anchorage independent growth when cultured in a semi-solid medium, indirectly confirming the lack of oncogenic transformation.

**Macroscopic aspect of the wound healing**
All wounds healed without severe infection and typical scars formed at the site of each wound. With the

### Table 1  Semi-quantitative scale for the histological parameters

| Parameter                                      | Score | 0      | 1      | 2      | 3      |
|-----------------------------------------------|-------|--------|--------|--------|--------|
| Re-epithelization rate                         | Early signs of re-epithelization | Regenerated mono-layered epithelium | Regenerated multi-layered epithelium | Differentiated multi-layered epithelium (stratum corneum) |
| Inflammatory infiltrate (white cells)         | None  | Few    | Fair   | Rich   |        |
| Collagen content in granulation tissue         | None  | Poor   | Moderate| High   |        |
| PCNA in epidermis and dermis (positive nuclei/mm of epidermis or mm² of dermis) | 0     | 1–9    | 10–30  | >30    |
Figure 2. Characterization of rabbit MSCs. A Morphology of bone marrow and adipose-derived mesenchymal stromal cells obtained from one rabbit. MSCs from both sources display the characteristic spindle-shaped morphology. Magnification x4. B Immunophenotype of culture-expanded ASCs obtained from one representative rabbit. ASCs were positive for CD90, CD29 and CD49e and negative for CD45 and CD10, as reported [20]. The immunophenotype of BM-MSCs was superimposable. C Osteogenic and adipogenic differentiation capacity of BM-MSCs and ASC. Differentiation into osteoblasts was demonstrated by the histological detection of Alkaline phosphatase activity (a) and calcium depositions positive for Alizarin Red (b); magnification x20. Differentiation into adipocytes was revealed by the formation of lipid droplets stained with Oil Red O (c); magnification x20. Non differentiated cells (negative ctrl) are reported.
macroscopic analysis, autologous ASC inoculation induced a more rapid and more complete wound healing process when compared with the other experimental conditions (Figure 3).

**Histological results**

**Semi-quantitative analysis of histological parameters**

Semi-quantitative assessment of the regenerated epithelial layer features, inflammatory infiltrate extent, collagen deposition and PCNA-positive nuclei in treated and control wounds, at 11 and 21 days, is reported in Table 2. In our study, the best and worst re-epithelization rates were noted after autologous ASC and autologous BM-MSC inoculation, respectively. Since no time effect was noted, we only reported the p values (obtained in the multivariable ordinal logistic regression models i.e. corrected for time) relative to group comparisons (Table 2).

When MSC inoculation numbers were considered, histological results were not different in wounds treated with $10 \times 10^6$ or $3 \times 10^6$ autologous ASCs (epithelial regeneration $p = 0.32$; inflammatory infiltrate $p = 0.34$; collagen deposition $p = 0.38$; PCNA-positive nuclei-epidermis $p = 0.26$, dermis $p = 0.68$).

When different sources were considered, ASC-treated wounds exhibited better regeneration of epithelial layers ($p < 0.001$), collagen deposition ($p < 0.001$) and PCNA-positive nuclei in epithelial regenerated epidermis ($p < 0.001$) compared to BM-MSC treated lesions.

**Re-epithelization, collagen deposition and cellular proliferation**

At 11 days, autologous ASC-treated wounds showed a more advanced re-epithelization in comparison with wounds treated under all other experimental conditions. Beneath the necrotic material, the epidermis was entirely regenerated and almost completely differentiated, with a thin *stratum corneum*. Only the central area of the wound had a single layer of epithelium. The dermis contained a small number of inflammatory cells; some small blood vessels, presumably newly formed, were evident, with only slight signs of edema (Figure 4, Panel 1). After 21 days of treatment, the skin was completely regenerated, with a perfectly differentiated epidermis (Figure 4, Panel 2).

Allogeneic ASC-treated wounds did not develop an entirely re-formed skin layer: a continuous mono-layer of epithelium was observed in most of the samples (Figure 4, Panel 3). At 21 days, the epithelium was multi-layered, but the central area of the wound never developed a *stratum corneum* (Figure 4, Panel 4). Connective tissue showed small amounts of inflammatory infiltration, with several dilated vessels.

---

**Figure 3** Skin regeneration at day 11 after autologous ASC injection vs control (a), autologous ASCs vs autologous BM-MSCs (b), allogeneic ASCs vs control (c), allogeneic ASCs vs autologous ASCs (d).
The wounds inoculated with BM-MSCs showed, in most cases, a small area devoid of epithelium (Figure 4, Panels 5 and 6), while the saline-treated wounds never developed a continuous epidermis (Figure 4, Panels 7 and 8).

In the Mallory trichrome-stained sections (Figure 5), all MSC-treated wounds showed higher blue staining density than the saline-treated wounds, revealing new collagen deposition. The amount of collagen visibly increased in autologous ASC-treated wounds where collagen was arranged in thick bundles of fibres (Figure 5, Panels 1 and 2). No differences were observed after 11 or 21 days of treatment.

Finally, the number of PCNA-positive nuclei in the epidermal basal layers of autologous ASC-treated wounds (Figure 6, Panels 1 and 2) was higher than in all other groups (Figure 6, Panels 7 and 8). The saline-treated wounds, however, displayed increased positivity for fibroblasts and endothelial cells.

Discussion

Skin is the largest organ of the human body and it has multiple functions in maintaining homeostasis. It forms an important barrier from the outside environment. Following skin injury, the damaged tissue is repaired through coordinated biological actions that constitute the cutaneous healing response. [1–4, 28].

Chronic wounds are an important and growing problem with an incidence of 5–7 million cases per person/years in the United States; and, about 50% do not respond to current treatment [6, 29, 30]. Moreover, skin grafting in children remains a challenge for pediatric surgeons and scientists.

The presence of MSCs in normal skin [31], their capacity to differentiate and to regulate immune and inflammatory responses suggest their role in wound healing [32–34]. For this reason the application of exogenous MSCs is a promising approach to treat non healing wounds.

Although BM-MSCs have been extensively used for cell therapy approaches in seminal experimental and clinical studies, adipose tissue has been increasingly employed as an abundant source of ASCs, especially in the field of reparative medicine [35]. Successful isolation, extensive proliferative capacities ex vivo, and their ability to secrete pro-angiogenic growth factors make adipose derived stem cells an ideal cell type for the treatment of non healing wounds [36–40], also in pediatric patients.

Topically delivered ASC have been shown to enhance granulation tissue formation in skin wounds improving outcome in wound healing. Skin wounds treated with ASC are characterized by an enhanced healing rate and less scar formation than control wounds [34].

It has been reported that the reparative effect of MSCs is mediated by paracrine signaling with release of biologically active molecules affecting cell migration, proliferation, and survival of the surrounding cells [1, 5, 6, 34]. Recent studies have documented that extracellular vesicles are a key component of paracrine secretion in many cell types, also including MSC [41–44].
Figure 4  Histological aspect of the skin regeneration after 11 and 21 days of treatment. Panel 1 after 11 days treatment with autologous ASCs, the epidermis was entirely regenerated and almost completely differentiated, with a thin stratum corneum (arrow) and some shedding of necrotic material (asterisk). The dermis contains a small number of inflammatory cells and some small blood vessels. Panel 2 after 21 days treatment, the skin was completely regenerated, with a perfectly differentiated epidermis. Panel 3 allogeneic ASC-treated wounds after 11 days display large areas devoid of epithelium or with a mono-layered or thin epidermis. Panel 4 after 21 days the epithelium was multi-layered, but no stratum corneum is evident. Connective tissue showed a small amount of inflammatory infiltration, with several dilated vessels. Panels 5, 6 the wounds inoculated with BM-MSCs show large areas devoid of epithelium after 11 days, as well as 21 days of treatment. Panels 7, 8 only early signs of re-epithelization are detectable in saline-treated samples; in correspondence with the de-epithelized area the connective tissue is infiltrated by numerous inflammatory cells (granulation tissue) and many vessels appear dilated. Haematoxilin and Eosin staining. Scale bar 200 μm; original mag. × 100.
MSCs contribute to the proliferative phase of wound healing and promote granulation and epithelialization by expressing growth factors such as VEGF, βFGF, and KGF [34]. Nakagawa et al. [45] suggested that MSCs, together with βFGF in a skin defect model, accelerate wound healing by showing that human MSCs differentiated into epithelium in a rat model. Shumakov et al. [46] observed that MSC transplantation onto deep burn

**Figure 5** Histological evaluation of collagen deposition at 11 and 21 days after different MSC treatments. Panels 1, 2 blue-stained collagen was clearly detectable in autologous ASC-treated areas, where collagen is arranged in thick bundles of fibres. Allogeneic ASC- (Panels 3, 4) and BM-MSC- treated wounds (Panels 5, 6) show a slightly higher blue staining density than the saline-treated wounds (Panels 7, 8). Eschar (asterisk). Mallory trichrome-staining. Scale bar 200 μm; original mag. × 100.
wound surfaces decreased inflammatory cell infiltration and accelerated the formation of new vessels and granulation tissue in rats.

Results from our histological analysis are in agreement with data reported in the literature [47, 48] and show differences in the wound healing progress among
experimental groups (different settings and sources). Improved re-epithelialization, reduced inflammatory infiltration and increased collagen deposition were observed in biopsies from wounds treated with allogeneic or autologous ASCs compared to autologous BM-MSCs and control-wounds. In autologous ASC-treated wounds increased cellular proliferation was also noted. ASC inoculation provided more rapid wound closure than BM-MSCs and controls. It is well known that excessive collagen accumulation may induce hypertrophic scar- ring [4]: interestingly, areas treated with autologous ASCs displayed a collagen fiber pattern similar to normal skin in shape, size and orientation, thus suggesting that ASCs improve restoration of skin architecture during wound healing.

The ability of MSCs to promote the transition from inflammatory to the proliferative phase is particularly critical for treating wounds where high levels of inflammation prevent healing [12].

In the present study, earlier re-epithelialization, replacement of the fibrin clot by granulated tissue and collagen deposition in autologous ASC-treated wounds were observed. The unsatisfactory results observed with BM-MSCs does not seem to be related to the lower number of inoculated cells. The data confirm that even though MSCs from different tissues have similar levels of surface antigen expression and differentiation ability, their rate of cell proliferation may be different and MSCs from various sources may have different therapeutic potentials [16].

The possible oncogenic transformation during in vitro expansion remains a critical consideration in MSC in vivo applications. While human MSCs are apparently resistant to transformation, animal MSCs, in particular mouse MSCs, are prone to acquire genomic abnormalities [49–51]. In order to exclude this possibility, in the present study, we used cells at early passages of in vitro expansion. Moreover, cell growth in a semi-solid medium and capability to reach senescence were evaluated, showing that ASCs and BM-MSCs expanded from rabbits were not transformed.

Wound healing in the pediatric patient is of utmost clinical and social importance, since scarrring can have aesthetic and psychological sequelae, from infancy to late adolescence. Despite the extensive data supporting the promising use of MSCs in dermal wound healing, clinical translation to the pediatric age remains limited [6, 52]. These data, from our preclinical study using young animals, could also be translated to regenerative medicine for the treatment of congenital and acquired skin lesions occurring in the pediatric age. At certain periods during childhood, such as in neonates or young infants, adipose tissue harvesting may be difficult or limited. Therefore, further studies focusing on the potential efficacy of cell therapy approaches in this particular area with the use of allogeneic ASCs obtained also from adult donors or cell free extracellular vesicles are urgently needed. Moreover, pre-clinical studies are necessary to validate the best skin regeneration technique, which would be used in translational pediatric surgery research in infants with disfiguring lesions.

Conclusions
Rabbit ASC can be isolated and expanded in vitro with relative abundance. Topical inoculation of ASCs provides restoration of skin architecture during cutaneous wound healing. The use of ASCs could be a promising solution to treat non healing or extended wounds; and would be applicable also in children. Future experimental studies should provide further perspectives on regenerative medicine in pediatric surgery.

Abbreviations
AP: alkaline phosphatase; ASCs: adipose stem cells; BM-MSCs: bone marrow mesenchymal stromal cells; DAB: 3,3’-diaminobenzidine; DMEM: Dulbecco’s modified eagle medium; FBS: fetal bovine serum; FITC: fluorescein isothiocyanate; H&E: haematoxylin and eosin; MNC: mononuclear cells; MSCs: mesenchymal stromal cells; PBS: phosphate-buffered saline; PCNA: proliferating cell nuclear antigen; PE: phycoerythrin; SA-β-gal: β-galactosidase; SVF: stromal vascular fraction.

Authors’ contributions
GP: conception and design, surgical support on animal, data analysis and interpretation, manuscript writing, final approval of the manuscript. MM: data collection. LA: data collection. SP: data analysis. VC: conception and design, data interpretation, manuscript writing, final approval of the manuscript. MD: conception and design, data interpretation, manuscript writing, final approval of the manuscript. MI: conception and design, data interpretation, manuscript writing, final approval of the manuscript. GM: data collection. DI: data collection. RM: conception and design, data analysis and interpretation, manuscript writing, final approval of the manuscript. MM: data collection. DI: data collection. SP: data analysis. VC: conception and design, data analysis and interpretation, manuscript writing, final approval of the manuscript. All authors read and approved the final manuscript.

Author details
1 Pediatric Surgery Unit, Fondazione IRCCS Policlinico San Matteo and University of Pavia, 27100 Pavia, Italy. 2 Immunology and Transplantation Laboratory/Cell Factory/ Pediatric Hematology/Oncology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 3 Biometry and Clinical Epidemiology Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 4 Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences for Children and Adults, University-Hospital of Modena and Reggio, Emilia, Italy. 5 Biometry and Clinical Epidemiology Unit, Scientific Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 6 Pediatric Unit, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.

Acknowledgements
This study was supported in part by Grants from the Fondazione IRCCS Policlinico San Matteo (“Stem cells in cutaneous wound healing in pediatric surgery” and “Fetal therapy for congenital malformations” projects). The authors thank Dr. E. Lenta and Dr. V. Viaggi for technical support in MSC expansion and differentiation and Dr. L. Kelly for English revision of the manuscript.
Compliance with ethical guidelines

Competing interests

The authors declare that they have no competing interests.

Received: 11 May 2015   Accepted: 24 June 2015

Published online: 08 July 2015

References

1. Buganza-Tepole A, Kuhl E (2013) Systems-based approaches toward wound healing. Pediatr Res 73:553–563
2. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453:14–32
3. Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:855–870
4. Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738–746
5. Jackson WM, Nesti LJ, Tuan RS (2012) Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med 1:144–149
6. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA (2012) Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med 1:142–149
7. Gurtner GC, Callaghan MJ, Longaker MT (2007) Progress and potential for regenerative medicine. Annu Rev Med 58:299–312
8. Stappenbeck TS, Miyoshi H (2009) The role of stromal stem cells in tissue regeneration and wound repair. Science 324:1666–1669
9. Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 25:2896–2902
10. Zahroric P, Koller J, Danisovic L, Bohac M (2014) Mesenchymal stem cells for chronic wounds therapy. Cell Tissue Bank (Epub ahead of print) (PubMed PMID: 24651970)
11. Zou JP, Huang S, Peng Y, Liu HW, Cheng B, Fu XB et al (2012) Mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs): potential role in healing cutaneous chronic wounds. Int J Low Extrem Wounds 11:244–253
12. Ennis WJ, Sun A, Bartholomew A (2013) Stem cells and healing: impact on inflammation. Adv Wound Care (New Rochelle) 2:369–378
13. Nuschke A (2014) Activity of mesenchymal stem cells in therapies for vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy 15:641–648
14. Stroia M, Viswanathan S, Daninas A, Slaby O, Michalek J (2012) Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem cells. Stem Cells Dev 21:2724–2752
15. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Danilkovitch-Miagkova A et al (1999) Transplantability and therapeutic effects of bone marrow- and cord blood-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309–313
16. Arneja JS, Gosain AK (2009) Giant congenital melanocytic nevi. Plast Reconstr Surg 123:369–377
17. Werner S, Grose R (2003) Regulation of wound healing by growth factors and cytokines. Physiol Rev 83:855–870
18. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Danilkovitch-Miagkova A et al (1999) Transplantability and therapeutic effects of bone marrow- and cord blood-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309–313
19. Arneja JS, Gosain AK (2009) Giant congenital melanocytic nevi. Plast Reconstr Surg 123:369–377
20. Sheridan RL, Greenhalgh D (2014) Special problems in burns. Surg Clin North Am 94:781–791
21. Brown M, Coffee T, Adenuga P, Yowler CJ (2014) Outcomes of outpatient management of pediatric burns. J Burn Care Res. 35:388–394
22. Wu LW, Wang YL, Christensen JM, Khalifian S, Schneeberger S, Raimondi G et al (2014) Donor age negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells. Transpl Immunol 30:122–127
23. Daubs MD, Tyser A, Lawrence BD, Sinclair SK, Patel AA, Adams J et al (2015) The effect of aging on posterior intertransverse lumbar fusion. A New Zealand white rabbit model. J Spinal Disord Tech 28:E115–E120
24. Piccinno MS, Veronesi E, Loschi P, Nettà O, Gioglio L (2012) Effects of thermal water on skin regeneration. Int J Mol Med 29:732–740
25. Diegelmann RF, Evans MC (2004) Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 9:283–289
26. Hansson SE, Bentz ML, Hematti P (2010) Mesenchymal stem cell therapy for nonhealing cutaneous wounds. Plast Reconstr Surg 125:510–516
27. Mustoe TA, O’Shaughnessy K (2006) Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg 117(7 Suppl):355–415
28. Sellheim K, Krali D (2010) Cutaneous mesenchymal stem cells: status of current knowledge, implications for dermatopathology. J Cutan Pathol 37:624–634
29. Hu WS, Rennert RC, McCadle A, Chung MT, Wallmsley GG, Longaker MT et al (2014) The role of stem cells during scarless skin wound healing. Adv Wound Care (New Rochelle) 3:304–314
30. King A, Balaji S, Kesswani SG, Crembleholme TM (2014) The role of stem cells in wound angiogenesis. Adv Wound Care (New Rochelle) 3:614–625
31. Hassan WU, Greiser U, Wang W (2014) Role of adipose-derived stem cells in wound healing. Wound Repair Regen 22:313–325
32. Meliga E, Stem BM, Duckers HI, Serrus PW (2007) Adipose-derived cells. Cell Transplant 16:963–970
33. Cherubino M, Rubin JP, Miljkovic N, Kelmenti-Doko A, Marra KG (2011) Adipose-derived stem cells for wound healing applications. Ann Plast Surg 66:210–215
34. Schaffer A, Bucher C (2007) Concise review: adipose tissue-derived stromal/stem cells–basic and clinical implications for novel cell-based therapies. Stem Cells 25:818–827
35. Kim YJ, Jeong JH (2014) Clinical application of adipose stem cells in plastic surgery. J Korean Med Sci 29:462–467
36. Toyserkani NM, Christensen ML, Sheikh SP, Sørensen JA (2014) Adipose-derived stem cells: new treatment for wound healing? Ann Plast Surg (Epub ahead of print) (PubMed PMID: 24691309)
37. McLaughlin MM, Marra KG (2013) The use of adipose-derived stem cells as sheets for wound healing. Organogenesis 9:70–81
38. Buza E, Gyorgy B, Nagy G, Falus A, Gay S (2014) Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 10:356–364
39. Feraabradia A, Del Fattore A, Luciano R, Muraca M, Tetti A, Muraca M (2013) Recent advances in mesenchymal stem cell immunomodulation. The role of microvesicles. Cell Transpl. doi: 10.3727/029636813x57022 (PubMed PMID: 24691309)
40. Tetta C, Ghigo E, Silengo L, Deregibus MC, Camussi G (2013) Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine 44:11–19
41. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM et al (2014) Adipocytic extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 103:530–541
42. Nakagawa H, Akita S, Fukui M, Fuji T, Akino K (2005) Human mesenchymal stem cells successfully improve skin-substitute wound healing. Br J Dermatol 153:29–36
43. Shumakov V, Onishchenko NA, Rasulov MF, Krasheninnikov ME, Zadencov VA (2003) Mesenchymal bone marrow stem cells more effectively stimulate regeneration of deep burn wounds than embryonic fibroblasts. Exp Cell Biol Med 136:192–195
47. Hong SJ, Jia SX, Xie P, Xu W, Leung KP, Mustoe TA (2013) Galiano RD Topically delivered adipose derived stem cells show an activated-fibroblast phenotype and enhance granulation tissue formation in skin wounds. PLoS One 8:e55640

48. Hanson SE, Kleinbeck KR, Cantu D, Kim J, Bentz ML, Faucher LD et al (2013) Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. J Tissue Eng Regen Med. doi:10.1002/term.1700

49. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A et al (2007) Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67:9142–9149

50. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V et al (2006) Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 24:1095–1103

51. Wang Y, Han ZB, Song YP, Han ZC (2012) Safety of mesenchymal stem cells for clinical application. Stem Cells Int 2012:652034

52. Salibian AA, Widgerow AD, Abrouk M, Evans GR (2013) Stem cells in plastic surgery: a review of current clinical and translational applications. Arch Plast Surg. 40:666–675